Pfizer’s Go-It-Alone Approach Nets $1.95bn COVID Vaccine Order From US Government
Supply agreement with the Health and Human Services Department and the Department of Defense reflects a profitable per dose price of $19.50 for an initial batch of 100 million doses of the vaccine candidate, pending FDA authorization or approval.
You may also be interested in...
As China gears up to the possible launch of its first vaccines against the coronavirus, supported by clearer regulations, many see the candidates as promising and cost-effective, although they may need more convincing data to be widely adopted. Relatively low projected per dose costs are generating interest in trials in multiple countries.
Cigna's Steve Miller suggests pharma is taking a responsible approach to pricing during the pandemic in a policy discussion convened by the Institute for Clinical and Economic Review on pricing models for COVID-19 drugs and vaccines.
Administration suggests Operation Warp Speed vaccines come with US FDA review speed advantage, but the agency backtracks on that assertion. FDA may need to get creative to ensure it has enough staff to quickly review all vaccines, expert says.